Market situation intensifies for Arzerra
Roche has won European approval for Arzerra rival Gazyvaro, while CHMP recommends extended approval of Janssen’s Imbruvica.
BY BENJAMIN WERNER CHRISTENSEN
The possibilities are increasing for Genmab’s cancer drug Arzerra, but the competitive situation is also intensifying on the European market. It might sound contradictory, but on closer inspection it shoudl make sense.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Arzerra is a break-even project for Genmab
For abonnenter
Arzerra outperformed by business partner
For abonnenter
“This is a huge disappointment in my career”
For abonnenter
